In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Inhaled Insulin is Dead. Long Live Inhaled Insulin

Executive Summary

In early March, Eli Lilly became the third major pharmaceutical company to scupper its inhaled insulin program. Almost immediately the blogosphere began nailing inhaled insulin's coffin shut. IN VIVO thinks it's still too soon to deliver a eulogy. One company, MannKind, continues undaunted, despite the setbacks for it's competitors, hoping to bring its inhaled insulin to market by 2010. Meantime, specialty pharmaceutical companies or glucose monitoring testing outfits might be interested in the inhaled programs spurned by Big Pharma, but only for the right price.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts